Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.

[1]  D A Smith,et al.  Relations between age, mineral density and mechanical properties of human femoral compacta. , 1976, Acta orthopaedica Scandinavica.

[2]  William M. O'Fallon,et al.  Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. , 1990 .

[3]  G. Rodan,et al.  The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  E. Opas,et al.  The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. , 1993, The Journal of clinical investigation.

[5]  C H Turner,et al.  Basic biomechanical measurements of bone: a tutorial. , 1993, Bone.

[6]  L. Mosekilde,et al.  Marked decrease in trabecular bone quality after five years of sodium fluoride therapy--assessed by biomechanical testing of iliac crest bone biopsies in osteoporotic patients. , 1994, Bone.

[7]  J. F. V. Vincent,et al.  Young’s moduli and shear moduli in cortical bone , 1996, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[8]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[9]  S. Cummings,et al.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.

[10]  H. Bolotin.  Inaccuracies inherent in dual-energy X-ray absorptiometry in vivo bone mineral densitometry may flaw osteopenic/osteoporotic interpretations and mislead assessment of antiresorptive therapy effectiveness. , 2001, Bone.

[11]  C. Jerome,et al.  Nonhuman primate models in skeletal research. , 2001, Bone.

[12]  D. Burr,et al.  Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. , 2001, Bone.

[13]  C. Turner,et al.  Effects of raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys , 2002, Menopause.

[14]  Toshitaka Nakamura,et al.  Reductions in Bone Mass, Structure, and Strength in Axial and Appendicular Skeletons Associated With Increased Turnover After Ovariectomy in Mature Cynomolgus Monkeys and Preventive Effects of Clodronate , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  M. Hochberg,et al.  Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. , 2002, The Journal of clinical endocrinology and metabolism.

[16]  R. Müller,et al.  Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. , 2003, Bone.

[17]  Colin R Dunstan,et al.  A Single‐Dose Placebo‐Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  Ego Seeman,et al.  Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. , 2004, Bone.

[19]  C. Christiansen,et al.  Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  D. Bauer,et al.  Change in Bone Turnover and Hip, Non‐Spine, and Vertebral Fracture in Alendronate‐Treated Women: The Fracture Intervention Trial , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  P. Kostenuik.  Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. , 2005, Current opinion in pharmacology.

[22]  Kozo Nakamura,et al.  Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL–RANK signaling system , 2005, Immunological reviews.

[23]  D. Burr,et al.  Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. , 2006, Bone.

[24]  P. Geusens,et al.  Effects of low-dose long-term sodium fluoride preventive treatment on rat bone mass and biomechanical properties , 2006, Calcified Tissue International.

[25]  P. Kostenuik,et al.  Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease , 2008, Osteoporosis International.

[26]  S. Cummings,et al.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.

[27]  M. Allen,et al.  Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs , 2007, Osteoporosis International.

[28]  D. Burr,et al.  Three Years of Alendronate Treatment Results in Similar Levels of Vertebral Microdamage as After One Year of Treatment , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  Toshitaka Nakamura,et al.  Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys. , 2008, Bone.

[30]  P. Kostenuik,et al.  Soluble RANKL Induces High Bone Turnover and Decreases Bone Volume, Density, and Strength in Mice , 2008, Calcified Tissue International.

[31]  Sundeep Khosla,et al.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. , 2008, Endocrine reviews.

[32]  D. Burr,et al.  Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate , 2009, Osteoporosis International.

[33]  C. Turner,et al.  Skeletal health: primate model of postmenopausal osteoporosis , 2009, American journal of primatology.

[34]  Jacques P. Brown,et al.  Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  F. Saad,et al.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer. , 2009, The New England journal of medicine.

[36]  Claus Christiansen,et al.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.

[37]  D. Burr,et al.  Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: Implications for subtrochanteric femoral fracture risk , 2009, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[38]  K. Michaëlsson,et al.  Simply ask them about their balance--future fracture risk in a nationwide cohort study of twins. , 2008, American journal of epidemiology.

[39]  P. Kostenuik,et al.  Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  Klaus Klaushofer,et al.  Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  A. LaCroix,et al.  Lasofoxifene in postmenopausal women with osteoporosis. , 2010, The New England journal of medicine.

[42]  P. Kostenuik,et al.  Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. , 2011, Bone.

[43]  J. S. San Martin,et al.  Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. , 2011, The Journal of clinical endocrinology and metabolism.